Get access

Applying proteomics to the diagnosis and treatment of ALS and related diseases

Authors

  • Robert Bowser PhD,

    Corresponding author
    1. Department of Pathology, University of Pittsburgh School of Medicine, BST S-420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA
    2. Center for ALS Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    • Department of Pathology, University of Pittsburgh School of Medicine, BST S-420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA
    Search for more papers by this author
  • David Lacomis MD

    1. Department of Pathology, University of Pittsburgh School of Medicine, BST S-420, 200 Lothrop Street, Pittsburgh, Pennsylvania 15261, USA
    2. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    3. Center for ALS Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Search for more papers by this author

Abstract

Protein-based biomarkers for amyotrophic lateral sclerosis (ALS) and other motor neuron diseases (MNDs) have many potential clinical utilities, including diagnostic, prognostic, and drug development indications. During the past decade a number of potential protein biomarkers have been proposed for MNDs. Further verification studies, followed by large validation and qualification studies, are required to advance these initial discoveries toward clinical use. Study of additional patient populations, including disease mimics, is required during the validation phase of biomarker development. Important regulatory issues are discussed that will affect the timing and strategy for biomarker assay development in ALS and other MNDs. The continued development of protein biomarkers for MNDs requires extensive collaboration between academic clinicians and scientists in conjunction with the biotechnology and pharmaceutical industries. Muscle Nerve, 2009

Ancillary